(0)
Despite global disruptions to family planning services due to the Covid-19 pandemic, WomanCare Global Trading CIC (DKT WomanCare) and Shanghai Dahua Pharmaceutical Co., Ltd. (Dahua) are proud to announce a price reduction of Levoplant, a two-rod contraceptive implant prequalified by the World Health Organization (WHO) for up to three years of use. Levoplant is currently registered and increasing the reproductive health autonomies of women in more than 30 countries around the world.
Levoplant will now be just
$6.70 USD (FOB) for qualified purchasers in FP2020 focus countries, a $0.20 decrease from the current access price of $6.90 USD and the second such reduction over the last three years. Despite Covid-19 and a general climate of significant cost increases across the pharmaceutical industry, especially for raw materials like levonorgestrel (the active pharmaceutical ingredient in Levoplant), this price reduction will help expand access to a quality contraceptive to those that need it most.